10-Q: Bone Biologics Faces Going Concern Doubt Amidst R&D Spending

Bone Biologics Corporation's Q2 2026 Form 10-Q highlights ongoing net losses and a substantial accumulated deficit, raising concerns about its ability to continue as a going concern despite recent capital raises.

Summary

• Bone Biologics Corporation filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $773,702 for the three months ended June 30, 2026, and a net loss of $1,539,690 for the six months ended June 30, 2026.
• As of June 30, 2026, the company had cash of $4,031,780, which, combined with proceeds from a July 2026 private placement, is expected to fund operations into the second quarter of 2027.
• The company has an accumulated deficit of approximately $89.7 million as of June 30, 2026.
• Research and development expenses increased by 61.13% to $308,747 for the three months ended June 30, 2026, compared to the prior year period.
• General and administrative expenses decreased by 10.26% to $499,359 for the three months ended June 30, 2026, compared to the prior year period.
• The company's ability to continue as a going concern is subject to substantial doubt, as noted by its independent auditors.
• A July 7, 2026, private placement provided net proceeds of approximately $2.7 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued net losses, significant accumulated deficit, and the substantial doubt raised about its ability to continue as a going concern, despite recent financing efforts.

Positives

• The company secured approximately $2.7 million in net proceeds from a private placement on July 7, 2026.
• Available cash, including the July 2026 private placement, is expected to fund operations into the second quarter of 2027.
• Research and development expenses decreased by 26.80% to $450,344 for the six months ended June 30, 2026, compared to the prior year period, potentially indicating improved cost management in R&D execution.
• General and administrative expenses decreased slightly by 0.73% to $1,162,816 for the six months ended June 30, 2026, compared to the prior year period.
• The company's lead product candidate, NELL-1/DBM, has received guidance from the FDA for classification as a device/drug combination product.
• A patent application regarding proprietary compositions of rhNELL-1 polypeptide was submitted in the second quarter of 2025.

Negatives

• The company incurred a net loss of $773,702 for the three months ended June 30, 2026, and $1,539,690 for the six months ended June 30, 2026.
• The company has an accumulated deficit of $89,670,059 as of June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year after the issuance date of the financial statements.
• Cash used in operating activities was $1,322,722 for the six months ended June 30, 2026.
• Research and development expenditures increased by 61.13% to $308,747 for the three months ended June 30, 2026, compared to the prior year period.
• The company relies on future financing, with no assurance that such financing will be consummated or obtained in sufficient amounts.
• If cash resources are insufficient, the company may be required to scale back or discontinue product development programs or operations.
• The company's common stock and warrants could be delisted from Nasdaq if it fails to meet the Market Value of Listed Securities (MVLS) Requirement.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt.
• There is no assurance that future financing will be available or on satisfactory terms.
• Insufficient cash resources could lead to scaling back or discontinuing product development programs or operations.
• The company's common stock and warrants could be delisted from Nasdaq if it fails to meet the MVLS Requirement.
• Delisting from Nasdaq could result in an inability to raise equity capital, loss of business partner confidence, a decrease in stock price, and limited trading activity.
• The company's success depends on obtaining and maintaining patents and product license rights.
• Clinical trials may encounter problems that cause delays or suspension.
• The company is subject to extensive regulation by governmental authorities, including the FDA.

Future Outlook

The company anticipates continued substantial investment in development activities for NELL-1 as it prepares for its pivotal clinical study. Operating expenditures for the next twelve months are estimated at $6.2 million. Available cash, including the July 2026 private placement, is expected to fund operations into the second quarter of 2027. The company will continue to seek additional debt and/or equity financing.

Management Comments

• The company's success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others.
• There can be no assurance that the company will not encounter problems in clinical trials that will cause the company or the FDA to delay or suspend clinical trials.
• If cash resources are insufficient to satisfy the company's on-going cash requirements, the company will be required to scale back or discontinue its product development programs, or obtain funds through strategic alliances that may require the company to relinquish rights to its technology, or substantially reduce or discontinue its operations entirely.

Industry Context

StockSavvy.ai notes that Bone Biologics operates in the highly regulated and capital-intensive medical device sector, specifically focusing on bone regeneration. The company's reliance on FDA approval for its NELL-1/DBM combination product places it in a competitive landscape where clinical trial success and regulatory hurdles are paramount. The ongoing need for significant capital to fund development and the inherent risks associated with clinical trials are common challenges for companies at this stage in the industry.

Comparison to Industry Standards

• Companies in the regenerative medicine and orthopedic device space often require substantial upfront investment in R&D and face lengthy regulatory approval processes, similar to Bone Biologics' situation with NELL-1/DBM.
• The 'going concern' issue is prevalent among early-stage biotech and medical device companies that have not yet achieved commercial revenue, necessitating continuous fundraising efforts.
• The valuation of warrant liabilities is a common accounting practice for companies issuing warrants, with fair value adjustments impacting the income statement.
• The use of ATM (At The Market) offerings is a standard method for small-cap companies to raise capital incrementally, as seen with Bone Biologics' use of H.C. Wainwright & Co.

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on its business, financial condition, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financing, risk of delisting from Nasdaq, and uncertainty regarding the company's going concern status.
• Creditors: Potential impact on ability to recover debts if the company ceases operations.
• Employees: Risk of scaled-back operations or discontinuation of product development programs if financing is insufficient.
• Business Partners: Potential loss of confidence and jeopardized ability to continue business if the company faces delisting or operational challenges.

Next Steps

• Continue to fund operations into the second quarter of 2027 with available cash and proceeds from the July 2026 private placement.
• Continue to attempt to raise additional debt and/or equity financing.
• Prepare for a pivotal clinical study in the United States for the NELL-1/DBM product candidate.
• Continue to develop and commercialize licensed products under the License Agreement with UCLA TDG.
• Monitor compliance with Nasdaq continued listing requirements, specifically the MVLS Requirement.

Key Dates

Recommendation

The company is in a critical stage with significant R&D investment and a clear path towards potential product approval, but faces substantial going concern risks and potential Nasdaq delisting. While the recent financing provides a runway, the lack of revenue and continued losses necessitate a cautious approach. A 'hold' recommendation reflects the speculative nature of the investment, balancing the long-term potential of its technology against the immediate financial and regulatory risks.

Keywords

bone regeneration, spinal fusion, NELL-1, DBM, medical device, clinical trials, FDA approval, biotechnology